Mitochondrial transport of K+ and Mg2+.

J. J. Diwan

DOI: https://doi.org/10.1016/S0304-4173(87)80001-0

Biochimica et Biophysica Acta

Abstract:

What problem does this paper attempt to address?

Chimeric Measles Virus (MV/RSV), Having Ectodomains of Respiratory Syncytial Virus (RSV) F and G Proteins Instead of Measles Envelope Proteins, Induced Protective Antibodies against RSV

Akihito Sawada,Takashi Ito,Yoshiaki Yamaji,Tetsuo Nakayama

DOI: https://doi.org/10.3390/vaccines9020156

2021-02-16

Vaccines

Abstract:In our previous study, fusion (F) or glyco (G) protein coding sequence of respiratory syncytial virus (RSV) was inserted at the P/M junction of the measles AIK-C vector (MVAIK), and the recombinant measles virus induced protective immune responses. In the present study, the ectodomains of measles fusion (F) and hemagglutinin (HA) proteins were replaced with those of RSV F and G proteins, and a chimeric MV/RSV vaccine was developed. It expressed F and G proteins of RSV and induced cytopathic effect (CPE) in epithelial cell lines (Vero, A549, and HEp-2 cells), but not in lymphoid cell lines (B95a, Jurkat, and U937 cells). A chimeric MV/RSV grew similarly to AIK-C with no virus growth at 39 °C. It induced NT antibodies against RSV in cotton rats three weeks after immunization through intramuscular route and enhanced response was observed after the second dose at eight weeks. After the RSV challenge with 106 PFU, significantly lower virus (101.4±0.1 PFU of RSV) was recovered from lung tissue in the chimeric MV/RSV vaccine group than in the MVAIK control group with 104.6±0.2 PFU (p < 0.001) and no obvious inflammatory pathological finding was noted. The strategy of ectodomain replacement in the measles virus vector is expected to lead to the development of safe and effective vaccines for other enveloped viruses.

immunology,medicine, research & experimental
Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses

Z Wang,L Hangartner,T I Cornu,L R Martin,A Zuniga,M A Billeter,H Y Naim

DOI: https://doi.org/10.1016/s0264-410x(00)00523-5

IF: 4.169

2001-03-21

Vaccine

Abstract:We have genetically engineered a panel of recombinant measles viruses (rMVs) that express from various positions within the MV genome either the HN or F surface glycoproteins of mumps virus (MuV) or the env, gag or pol proteins from simian immunodeficiency virus (SIV). All rMVs were rescued from the respective antigenomic plasmid constructs; progeny viruses replicated comparably to the progenitor Edmonston B MV, but showed slight propagation retardation, which was dependent on the size and nature of the expressed proteins and on the genomic position of the inserts. All transgenes except that encoding mumps F glycoprotein were faithfully maintained and expressed even after virus amplification by 10(20). Our results suggest possible applications of rMVs as live-attenuated, multivalent vaccines against retroviruses such as SIV and HIV as well as other pathogens more distantly related to MV than MuV.
Pathogenicity and Immunogenicity of Recombinant Methyltransferase-Defective Vesicular Stomatitis Virus

ZHANG Xiao-dong,SUN Jing,LI Jian-rong,YU Lian

DOI: https://doi.org/10.3785/j.issn.1008-9209.2011.04.001

2011-01-01

Abstract:To prevent the vesicular stomatitis virus(VSV) disease, using a panel of recombinant VSV(E1764A,S1827A,Y1650A,and F1691A) that were defective in mRNA cap methylation as vaccine to inoculate five-week-old BALB/c female mice through oral route with 1×106 PFU,the pathogenicity and immunogenicity of these viruses were determined.The result showed that recombinant S1827A,Y1650A,F1691A were attenuated in mice and E1764A was still pathogenic to mice.The immunized mice were challenged with wild type VSV.Mice immunized with S1827A and Y1650A trigged a high level of neutralizing antibody and were protected from virulent challenge.Taken together,the results above demonstrated that methyltransferase(MTase)-defective VSV(S1827A and Y1650A) were not only attenuated in animals,but also exhibited excellent immunogenicity.Therefore,MTase-defective viruses will be good live vaccine candidates against VSV.
Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines

Aileen Ebenig,Mona V Lange,Michael D Mühlebach

DOI: https://doi.org/10.1038/s41541-022-00543-4

2022-10-15

npj Vaccines

Abstract:Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA technologies, combined with systems to generate infectious negative-strand RNA viruses on the basis of viral genomes encoded on plasmid DNA in the 1990s, paved the way to generate recombinant, vaccine strain-derived MeVs. These live-attenuated vaccine constructs can encode and express additional foreign antigens during transient virus replication following immunization. Effective humoral and cellular immune responses are induced not only against the MeV vector, but also against the foreign antigen cargo in immunized individuals, which can protect against the associated pathogen. This review aims to present an overview of the versatility of this vaccine vector as platform technology to target various diseases, as well as current research and developmental stages, with one vaccine candidate ready to enter phase III clinical trials to gain marketing authorization, MV-CHIK.
Cloning of Hemagglutinin Gene of Edmonston Vaccine Strain of Measles Virus and Fusion Protein Expression in Escherichia Coli

YANG Yue-feng,LUO Dong-hui,JIA Hong-yu,ZHOU Lin-fu

DOI: https://doi.org/10.3969/j.issn.1671-9638.2005.02.002

2005-01-01

Abstract:Objective To construct recombinant plasmid MV-H-pGEMEX-1 and express fusion proteins in E.coli in order to lay a foundation for further study on early diagnostic antibody and measles virus (MV) subunit vaccine. Methods MV genomic RNA was extracted from the live attenuated vaccine (Edmonston strain) and H gene was amplified by RT-PCR. After digested by Bam-HI and Hind-Ⅲ enzymes, the H gene was inserted into expression plasmid pGEMEX-1 by T4 DNA ligase, the recombinant plasmid MV-H-pGEMEX-1 was transformed into E.coli BL21 (DE3) and JM109 (DE3) and induced by IPTG. The expression of H protein was analyzed by SDS-PAGE. Results The product of RT-PCR was 1 900 bp which corresponded to MV-H. PCR analysis, enzymatic digestion and DNA sequence analysis verified that the H gene had been inserted into the vector in the correct direction, and sequence analysis showed that compared with the reported H gene published in NCBI, the homology of the sequences was 99.4%, while the amino acid homology was 98.8%. The molecular weight of fusion proteins expressed by E.coli JM109 (DE3) and BL21 (DE3) in SDS-PAGE corresponded to calculated molecular masses. Conclusions Recombinant expression plasmid MV-H-pGEMEX-1 was successfully constructed, which expressed fusion protein in E.coli.
A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection

Kathrin Endt,Yvonne Wollmann,Jana Haug,Constanze Bernig,Markus Feigl,Alexander Heiseke,Markus Kalla,Hubertus Hochrein,Mark Suter,Paul Chaplin,Ariane Volkmann

DOI: https://doi.org/10.3389/fimmu.2022.841471

IF: 7.3

2022-06-15

Frontiers in Immunology

Abstract:Respiratory syncytial virus (RSV) causes a respiratory disease with a potentially fatal outcome especially in infants and elderly individuals. Several vaccines failed in pivotal clinical trials, and to date, no vaccine against RSV has been licensed. We have developed an RSV vaccine based on the recombinant Modified Vaccinia Virus Ankara-BN ® (MVA-RSV), containing five RSV-specific antigens that induced antibody and T-cell responses, which is currently tested in clinical trials. Here, the immunological mechanisms of protection were evaluated to determine viral loads in lungs upon vaccination of mice with MVA-RSV followed by intranasal RSV challenge. Depletion of CD4 or CD8 T cells, serum transfer, and the use of genetically engineered mice lacking the ability to generate either RSV-specific antibodies (T11μMT), the IgA isotype (IgA knockout), or CD8 T cells (β2M knockout) revealed that complete protection from RSV challenge is dependent on CD4 and CD8 T cells as well as antibodies, including IgA. Thus, MVA-RSV vaccination optimally protects against RSV infection by employing multiple arms of the adaptive immune system.

immunology
A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9

Cindy Hörner,Anna H Fiedler,Bianca S Bodmer,Lisa Walz,Vivian A Scheuplein,Stefan Hutzler,Mikhail N Matrosovich,Veronika von Messling,Michael D Mühlebach

DOI: https://doi.org/10.1038/s41541-023-00643-9

2023-03-24

npj Vaccines

Abstract:A novel Influenza A virus (subtype H7N9) emerged in spring 2013 and caused considerable mortality in zoonotically infected patients. To be prepared for potential pandemics, broadly effective and safe vaccines are crucial. Recombinant measles virus (MeV) encoding antigens of foreign pathogens constitutes a promising vector platform to generate novel vaccines. To characterize the efficacy of H7N9 antigens in a prototypic vaccine platform technology, we generated MeVs encoding either neuraminidase (N9) or hemagglutinin (H7). Moraten vaccine strain-derived vaccine candidates were rescued; they replicated with efficiency comparable to that of the measles vaccine, robustly expressed H7 and N9, and were genetically stable over 10 passages. Immunization of MeV-susceptible mice triggered the production of antibodies against H7 and N9, including hemagglutination-inhibiting and neutralizing antibodies induced by MVvac2-H7(P) and neuraminidase-inhibiting antibodies by MVvac2-N9(P). Vaccinated mice also developed long-lasting H7- and N9-specific T cells. Both MVvac2-H7(P) and MVvac2-N9(P)-vaccinated mice were protected from lethal H7N9 challenge.
RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models

Freek Cox,Eirikur Saeland,Anne Thoma,Ward van den Hoogen,Lisanne Tettero,Joke Drijver,Cornelis Vaneman,Yolinda van Polanen,Tina Ritschel,Arangassery Rosemary Bastian,Benoit Callendret,Roland Zahn,Leslie van der Fits

DOI: https://doi.org/10.3390/vaccines11030672

2023-03-17

Vaccines

Abstract:RSV is divided into two antigenic subtypes, RSV A and RSV B, which is largely based on the variation in the G protein, while the fusion protein F is more conserved and a target for antibody-mediated neutralization. Here we evaluate the breadth of the protective immune responses across RSV A and RSV B subtypes, induced by vaccines based on the RSV A-based fusion protein, stabilized in the prefusion conformation (preF) in preclinical models. Immunization of naïve cotton rats with preF subunit or preF encoded by a replication incompetent Adenoviral 26, induced antibodies capable of neutralizing recent RSV A and RSV B clinical isolates, as well as protective efficacy against a challenge with RSV A and RSV B strains. Similarly, induction of cross-neutralizing antibodies was observed after immunization with Ad26-encoded preF, preF protein or a mix of both (Ad26/preF protein) in RSV pre-exposed mice and African Green Monkeys. Transfer of serum of human subjects immunized with Ad26/preF protein into cotton rats provide protection against challenges with both RSV A and RSV B, with complete protection against both strains observed in the lower respiratory tract. In contrast, almost no protection against RSV A and B infection was observed after the transfer of a human serum pool isolated pre-vaccination. These results collectively show that the RSV A-based monovalent Ad26/preF protein vaccine induced neutralizing antibodies, as well as protection against both RSV A and RSV B subtypes in animals, including by passive transfer of human antibodies alone, suggesting that clinical efficacy against both subtypes can be achieved.

immunology,medicine, research & experimental
Involvement of capsular polysaccharide via a TLR2/NF-kappaB pathway in Vibrio vulnificus-induced IL-8 secretion of human intestinal epithelial cells.

B. Lee,Myun Soo Kim,S. Choi,Tae Sung Kim

DOI: https://doi.org/10.3892/IJMM_00000380

IF: 5.314

2010-04-01

International Journal of Molecular Medicine

Abstract:In a previous study, we reported that a wbpP gene mutation in Vibrio vulnificus was significantly impaired in its ability to synthesize surface capsular polysaccharide (CPS). In this study, we evaluated the functions of the V. vulnificus capsular polysaccharide on interleukin (IL)-8 production, as well as its underlying mechanisms in human intestinal epithelial cells. The CPS-defective wbpP mutant induced significantly lower levels of IL-8 production, IL-8 gene promoter activation and NF-kappaB activity in INT-407 cells than was noted with the wild-type or wbpP-complemented V. vulnificus. The expression levels of Toll-like receptor (TLR)2 mRNA and protein were also found to be lower in INT-407 cells infected with the CPS-defective wbpP mutant than in those cells infected with the wild-type or the wbpP-complemented strains. Additionally, the treatment of INT-407 cells with anti-TLR2 antibody proved to significantly block IL-8 production and NF-kappaB minimal promoter activity induced by the wild-type or the wbpP-complemented strains. Furthermore, purified V. vulnificus CPS was found to significantly induce IL-8 production and NF-kappaB activation, both of which were inhibited upon the addition of the anti-TLR2 antibody. Taken together, these results demonstrate that V. vulnificus capsular polysaccharide is involved in the induction of IL-8 production of human intestinal epithelial cells via a TLR2/NF-kappaB-dependent pathway.
MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination

Yeonsu Kim,Xiaoyan Zheng,Kathrin Eschke,M Zeeshan Chaudhry,Federico Bertoglio,Adriana Tomić,Astrid Krmpotić,Markus Hoffmann,Yotam Bar-On,Julia Boehme,Dunja Bruder,Thomas Ebensen,Linda Brunotte,Stephan Ludwig,Martin Messerle,Carlos Guzman,Ofer Mandelboim,Michael Hust,Stefan Pöhlmann,Stipan Jonjić,Luka Čičin-Šain

DOI: https://doi.org/10.1038/s41423-021-00814-5

Abstract:Global pandemics caused by influenza or coronaviruses cause severe disruptions to public health and lead to high morbidity and mortality. There remains a medical need for vaccines against these pathogens. CMV (cytomegalovirus) is a β-herpesvirus that induces uniquely robust immune responses in which remarkably large populations of antigen-specific CD8+ T cells are maintained for a lifetime. Hence, CMV has been proposed and investigated as a novel vaccine vector for expressing antigenic peptides or proteins to elicit protective cellular immune responses against numerous pathogens. We generated two recombinant murine CMV (MCMV) vaccine vectors expressing hemagglutinin (HA) of influenza A virus (MCMVHA) or the spike protein of severe acute respiratory syndrome coronavirus 2 (MCMVS). A single injection of MCMVs expressing either viral protein induced potent neutralizing antibody responses, which strengthened over time. Importantly, MCMVHA-vaccinated mice were protected from illness following challenge with the influenza virus, and we excluded that this protection was due to the effects of memory T cells. Conclusively, we show here that MCMV vectors induce not only long-term cellular immunity but also humoral responses that provide long-term immune protection against clinically relevant respiratory pathogens.
Protective efficacy of a novel recombinant influenza virus carrying partial human metapneumovirus F protein epitopes

Fang Sun,Guanglin Lei,Chongyu Tian,Zhifang Bai,Changqing Bai,Yufeng Li,Zhuoya Deng,Hao Yang,Cong Li,Zhongpeng Zhao,Yan Niu,Penghui Yang

DOI: https://doi.org/10.1080/21505594.2023.2284515

IF: 5.428

2023-11-16

Virulence

Abstract:Human metapneumovirus (HMPV) is a leading cause of acute respiratory tract infections in infants and children. Currently, no approved HMPV vaccine is available. We developed a novel recombinant influenza virus, which carried partial HMPV F protein (HMPV-F) epitopes, utilizing reverse genetics. The novel single-stranded RNA virus, termed rFLU-HMPV/F-NA, was synthesized in the neuraminidase (NA) fragment of influenza virus A/PuertoRico/8/34 (PR8). The morphological characteristics of rFLU-HMPV/F-NA were consistent with the wild-type flu virus. The virus could passage in specific pathogen-free (SPF) chicken embryos for at least five consecutive generations with haemagglutinin (HA) titres of 28-9 or 8-9LogTCID50/mL. BALB/c mice were intranasally immunized at 21-day intervals with 104 TCID50 (low-dose group) or 106 TCID50 (high-dose group) rFLU-HMPV/F-NA, and PBS or PR8 vaccine was used for the control group. rFLU-HMPV/F-NA induced robust humoral, mucosal, and cellular immune responses in vivo in a dose-dependent manner. More importantly, wt clinical HMPV isolate challenge studies showed that rFLU-HMPV/F-NA provided significant immune protection against HMPV infection compared to the PBS or PR8 vaccine control group, as shown by improved histopathological changes and reduced viral titres in the lungs of immunized mice post-challenge. These findings demonstrate that rFLU-HMPV/F-NA has potential as a promising HMPV candidate vaccine and warrants further investigation into its control of HMPV infection.
[Acutrak headless compression screw fixation for the treatment of scaphoid non-union].

Bing Xie,Jing Tian,Bing-Sheng Liu,Yan-feng Jing,Hai-Peng Xue,Da-Peng Zhou,L. Xiang

2014-03-01

Abstract:OBJECTIVE To evaluate the early clinical and radiographic outcome of scaphoid non-unions treated with Acutrak headless compression screw. METHODS From January 2008 to July 2011,21 patients with scaphoid non-union were treated in our department. There were 18 males and 3 females with a mean age of (23.6 +/- 4.6) years; 12 cases were on right hand and 9 were on left. According to Herbert-Fisher classification, there were 10 cases with type D1, 7 cases with type D2, 3 cases with type D3, and 1 case with type D4. The mean time from injury to operation was (12.4 +/- 2.7) months. All patients were treated with Acutrak headless compression screw fixation (6 cases received 2 screws fixation, 15 cases received 1 screw fixation, and Matti-Russe bone grafting was applied in 7 cases). The carpal height, the scaphoid index and changes of the scapholunate angle were assessed before and after the operation. Range of motion and grip strength were recorded and the wrist function was assessed according to the Patient-Rated Wrist Evaluation (PRWE). RESULTS Average duration of follow-up was (21.3 +/- 3.6) months. All the patients attained radiological union in a mean time of (13.3 +/- 2.4) weeks following the operation. No obvious complications were recorded. The surgical treatment allowed the preoperative mean scaphoid index of 0.61 +/- 0.13 and the preoperative mean scapholunate angle of (59.4 +/- 6.8) degree to be improved to 0.69 +/- 0.10 and (44.3 +/- 8.2)degree postoperatively, respectively. There was a substantial improvement in grip strength and pain amelioration after surgery. The preoperative mean PRWE score of 45.2 +/- 4.7 was improved to 76.1 +/- 5.2 postoperatively. All patients returned back to the original work,the average time from surgery to work was (6.0 +/- 1.1) months. CONCLUSION For scaphoid non-unions, Acutrak headless compression screw fixation can provide anatomical reduction, provide satisfactory results with a high union rate, well return of function and minimal complications in the early stage.
Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats

Basavaraj Binjawadagi,Yuanmei Ma,Rashmi Binjawadagi,Kelsey Brakel,Olivia Harder,Mark Peeples,Jianrong Li,Stefan Niewiesk

DOI: https://doi.org/10.1128/JVI.02345-20

IF: 6.549

2021-02-25

Journal of Virology

Abstract:Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract (LRT) infections, with increased severity in high-risk human populations, such as infants, the immunocompromised, and the elderly. Although the virus was identified more than 60 years ago, there is still no licensed vaccine available. Over the years, several vaccine delivery strategies have been evaluated. In this study, we developed two recombinant vesicular stomatitis virus (rVSV) vector-based vaccine candidates expressing the RSV-G (attachment) protein (rVSV-G) or F (fusion) protein (rVSV-F). All vectors were evaluated in the cotton rat animal model for their in vivo immunogenicity and protective efficacy against an RSV-A2 virus challenge. Intranasal (i.n.) delivery of rVSV-G and rVSV-F together completely protected the lower respiratory tract (lungs) at doses as low as 10 3 PFU. In contrast, doses greater than 10 6 PFU were required to protect the upper respiratory tract (URT) completely. Reimmunization of RSV-immune cotton rats was most effective with rVSV-F. In immunized animals, overall antibody responses were sufficient for protection, whereas CD4 and CD8 T cells were not necessary. A prime-boost immunization regimen increased both protection and neutralizing antibody titers. Overall, mucosally delivered rVSV-vector-based RSV vaccine candidates induce protective immunity and therefore represent a promising immunization regimen against RSV infection. IMPORTANCE Even after decades of intensive research efforts, a safe and efficacious RSV vaccine remains elusive. Expression of heterologous antigens from rVSV vectors has demonstrated several practical and safety advantages over other virus vector systems and live attenuated vaccines. In this study, we developed safe and efficacious vaccine candidates by expressing the two major immunogenic RSV surface proteins in rVSV vectors and delivering them mucosally in a prime-boost regimen. The main immune parameter responsible for protection was the antibody response. These vaccine candidates induced complete protection of both the upper and lower respiratory tracts.

virology
Diagnostic performance of venous lactate on arrival at the emergency department for myocardial infarction.

M. Gatien,I. Stiell,A. Wielgosz,D. Ooi,J. Lee

DOI: https://doi.org/10.1197/J.AEM.2004.10.012

2005-02-01

Academic Emergency Medicine

Abstract:OBJECTIVES To determine the sensitivity of the venous lactate level at presentation for acute myocardial infarction (AMI) in emergency department (ED) patients with chest pain. METHODS A prospective, double-blind observational study was done in a tertiary care ED. From January to April 2000, all consecutive patients presenting with chest pain were eligible. Lactate level was obtained on arrival and compared with two criterion standards for the diagnosis of AMI: the World Health Organization (WHO) and the Joint European Society of Cardiology/American College of Cardiology Committee (ESC/ACC) classifications. A lactate level greater than 1.50 mmol/L was considered positive. RESULTS Between January and April 2000, 718 patients were enrolled. By the WHO criteria, 64 patients suffered an AMI, of whom 59 had an elevated lactate level, yielding a sensitivity of 92% (95% CI = 86% to 99%), a specificity of 44% (95% CI = 40% to 48%), and a negative predictive value (NPV) of 98% (95% CI = 97% to 99%). For all patients presenting with more than two hours of chest pain (n=34), the lactate level was elevated. When using the ESC/ACC criteria, 100 patients sustained an AMI, of whom 88 had an elevated lactate level, yielding a sensitivity of 88% (95% CI = 82% to 94%), a specificity of 46% (95% CI = 42% to 50%), and an NPV of 96% (95% CI = 94% to 98%). CONCLUSIONS Venous lactate level at presentation is highly sensitive for the diagnosis of AMI, particularly in patients with more than two hours of chest pain. Given its limitations in specificity and ability to detect creatine kinase-MB-negative/troponin-positive microinfarcts, further research is needed to determine how lactate can complement other cardiac enzymes in risk-stratifying all acute coronary syndromes.
Measles Virus-Based Vaccine Expressing Membrane-Anchored Spike of SARS-CoV-2 Inducing Efficacious Systemic and Mucosal Humoral Immunity in Hamsters

Zhi-Hui Yang,Yan-Li Song,Jie Pei,Song-Zhuang Li,Rui-Lun Liu,Yu Xiong,Jie Wu,Yuan-Lang Liu,Hui-Fen Fan,Jia-Hui Wu,Ze-Jun Wang,Jing Guo,Sheng-Li Meng,Xiao-Qi Chen,Jia Lu,Shuo Shen

DOI: https://doi.org/10.3390/v16040559

2024-04-03

Viruses

Abstract:As SARS-CoV-2 continues to evolve and COVID-19 cases rapidly increase among children and adults, there is an urgent need for a safe and effective vaccine that can elicit systemic and mucosal humoral immunity to limit the emergence of new variants. Using the Chinese Hu191 measles virus (MeV-hu191) vaccine strain as a backbone, we developed MeV chimeras stably expressing the prefusion forms of either membrane-anchored, full-length spike (rMeV-preFS), or its soluble secreted spike trimers with the help of the SP-D trimerization tag (rMeV-S+SPD) of SARS-CoV-2 Omicron BA.2. The two vaccine candidates were administrated in golden Syrian hamsters through the intranasal or subcutaneous routes to determine the optimal immunization route for challenge. The intranasal delivery of rMeV-S+SPD induced a more robust mucosal IgA antibody response than the subcutaneous route. The mucosal IgA antibody induced by rMeV-preFS through the intranasal routine was slightly higher than the subcutaneous route, but there was no significant difference. The rMeV-preFS vaccine stimulated higher mucosal IgA than the rMeV-S+SPD vaccine through intranasal or subcutaneous administration. In hamsters, intranasal administration of the rMeV-preFS vaccine elicited high levels of NAbs, protecting against the SARS-CoV-2 Omicron BA.2 variant challenge by reducing virus loads and diminishing pathological changes in vaccinated animals. Encouragingly, sera collected from the rMeV-preFS group consistently showed robust and significantly high neutralizing titers against the latest variant XBB.1.16. These data suggest that rMeV-preFS is a highly promising COVID-19 candidate vaccine that has great potential to be developed into bivalent vaccines (MeV/SARS-CoV-2).

virology
Recombinant rabies virus expressing chimeric Omp31/sodC or AHCY gene from Brucella melitensis elicits high level of antibodies and secretary cytokines in mice

Zhenguang Li,Hongwei Zhu,Yanling Yang,Fengxue Wang,Menghang Wang,Na Sun,Shipeng Cheng,Zhen F. Fu,Yongjun Wen

DOI: https://doi.org/10.21203/rs.2.16210/v1

2019-10-18

Abstract:Abstract Background: The rabies virus (RV) vector LBNSE expressing foreign antigens has shown considerable promise as vaccines against viral and bacteria diseases, which is effective and safe. We produced a new RV-based vaccine vehicle expressing Brucella melitensis Omp31/sodC or AHCY gene by reverse genetics technology. The aim of this study was to investigate the cellular and humoral immunity of recombinant viruses. Results: The recombinant virus rLBNSE-SOD and rLBNSE-AHC retained growth properties similar to those of vector rLBNSE both in BSR and mNA cell culture. The Omp31/SODC and AHCY gene was expressed and detected by immunostaining. To compare the immunogenicity of LBNSE-SOD and LBNSE-AHC, mice were immunized with each of recombinant virus by intramuscular (i.m.). Then mice were bled at days 7, 14 after the immunization for the measurement of cytokines and virus neutralizing antibody (VNAs). The parent virus (LBNSE) without expression of any foreign molecules was included for comparison. It was found that mice inoculated with LBNSE-SOD and LBNSE-AHC showed no any signs of disease and exhibited seroconversion against RV. Our findings showed that mice were immunized with each of these recombinant RVs by intramuscular (i.m.) developed efficacy cellular and humoral immunity. The mRNA level of cytokines (IFN-γ and IL-2; IL-4 and IL-10) and VNA level against rabies virus in the blood of mice were increasing after immunization with recombinant RVs. There were no obvious histopathological changes in the brain samples of all mice. Conclusions: The studies suggested that recombinant RVs expressing Omp31/SodC or AHCY gene would elicit high level of antibodies and secretary cytokines and provided a promising vaccine candidate in mice.
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

Amy S. Espeseth,Pedro J. Cejas,Michael P. Citron,Dai Wang,Daniel J. DiStefano,Cheryl Callahan,Gregory O’ Donnell,Jennifer D. Galli,Ryan Swoyer,Sinoeun Touch,Zhiyun Wen,Joseph Antonello,Lan Zhang,Jessica A. Flynn,Kara S. Cox,Daniel C. Freed,Kalpit A. Vora,Kapil Bahl,Andrew H. Latham,Jeffrey S. Smith,Marian E. Gindy,Giuseppe Ciaramella,Daria Hazuda,Christine A. Shaw,Andrew J. Bett

DOI: https://doi.org/10.1038/s41541-020-0163-z

2020-02-14

npj Vaccines

Abstract:Abstract The RSV Fusion (F) protein is a target for neutralizing antibody responses and is a focus for vaccine discovery; however, the process of RSV entry requires F to adopt a metastable prefusion form and transition to a more stable postfusion form, which displays less potent neutralizing epitopes. mRNA vaccines encode antigens that are translated by host cells following vaccination, which may allow conformational transitions similar to those observed during natural infection to occur. Here we evaluate a panel of chemically modified mRNA vaccines expressing different forms of the RSV F protein, including secreted, membrane associated, prefusion-stabilized, and non-stabilized structures, for conformation, immunogenicity, protection, and safety in rodent models. Vaccination with mRNA encoding native RSV F elicited antibody responses to both prefusion- and postfusion-specific epitopes, suggesting that this antigen may adopt both conformations in vivo. Incorporating prefusion stabilizing mutations further shifts the immune response toward prefusion-specific epitopes, but does not impact neutralizing antibody titer. mRNA vaccine candidates expressing either prefusion stabilized or native forms of RSV F protein elicit robust neutralizing antibody responses in both mice and cotton rats, similar to levels observed with a comparable dose of adjuvanted prefusion stabilized RSV F protein. In contrast to the protein subunit vaccine, mRNA-based vaccines elicited robust CD4+ and CD8+ T-cell responses in mice, highlighting a potential advantage of the technology for vaccines requiring a cellular immune response for efficacy.

immunology,medicine, research & experimental
Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice

Hirofumi Kato,Mutsuyo Takayama-Ito,Itoe Iizuka-Shiota,Shuetsu Fukushi,Guillermo Posadas-Herrera,Madoka Horiya,Masaaki Satoh,Tomoki Yoshikawa,Souichi Yamada,Shizuko Harada,Hikaru Fujii,Miho Shibamura,Takuya Inagaki,Kinjiro Morimoto,Masayuki Saijo,Chang-Kweng Lim

DOI: https://doi.org/10.1371/journal.pone.0223684

IF: 3.7

2019-10-07

PLoS ONE

Abstract:Middle East respiratory syndrome-coronavirus (MERS-CoV) is an emerging virus that causes severe disease with fatal outcomes; however, there are currently no approved vaccines or specific treatments against MERS-CoV. Here, we developed a novel bivalent vaccine against MERS-CoV and rabies virus (RV) using the replication-incompetent P-gene-deficient RV (RVΔP), which has been previously established as a promising and safe viral vector. MERS-CoV spike glycoprotein comprises S1 and S2 subunits, with the S1 subunit being a primary target of neutralizing antibodies. Recombinant RVΔP, which expresses S1 fused with transmembrane and cytoplasmic domains together with 14 amino acids from the ectodomains of the RV-glycoprotein (RV-G), was developed using a reverse genetics method and named RVΔP-MERS/S1. Following generation of RVΔP-MERS/S1 and RVΔP, our analysis revealed that they shared similar growth properties, with the expression of S1 in RVΔP-MERS/S1-infected cells confirmed by immunofluorescence and western blot, and the immunogenicity and pathogenicity evaluated using mouse infection experiments. We observed no rabies-associated signs or symptoms in mice inoculated with RVΔP-MERS/S1. Moreover, virus-specific neutralizing antibodies against both MERS-CoV and RV were induced in mice inoculated intraperitoneally with RVΔP-MERS/S1. These findings indicate that RVΔP-MERS/S1 is a promising and safe bivalent-vaccine candidate against both MERS-CoV and RV.

multidisciplinary sciences
Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease

Yu-Na Lee,Hye Suk Hwang,Min-Chul Kim,Young-Tae Lee,Jong Seok Lee,Martin L Moore,Sang-Moo Kang

DOI: https://doi.org/10.1016/j.antiviral.2014.12.009

Abstract:Respiratory syncytial virus (RSV) is the leading cause of viral bronchiolitis in both children and the elderly. There is no vaccine available for the prevention of RSV infection. Here, we generated recombinant influenza virus (PR8/RSV.HA-F) expressing an RSV F243-294 neutralizing epitope in the hemagglutinin (HA) as a chimeric protein. Neutralizing antibodies specific for both RSV and influenza virus were induced by a single intranasal immunization of mice with PR8/RSV.HA-F. Mice that were immunized with PR8/RSV.HA-F were protected against RSV infection comparable with live RSV as evidenced by significant reduction of RSV lung viral loads, as well as the absence of lung eosinophilia and RSV-specific cellular immune responses. In contrast, formalin-inactivated RSV-immunized mice showed severe disease and high cellular immune responses in lungs after RSV infection. These findings support a concept that recombinant influenza virus carrying the RSV F243-294 neutralizing epitope can be developed as a promising RSV vaccine candidate which induces protective neutralizing antibodies but avoids lung immunopathology.
Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice

Daniela Ogonczyk-Makowska,Pauline Brun,Clémence Vacher,Caroline Chupin,Clément Droillard,Julie Carbonneau,Emilie Laurent,Victoria Dulière,Aurélien Traversier,Olivier Terrier,Thomas Julien,Marie Galloux,Stéphane Paul,Jean-François Eléouët,Julien Fouret,Marie-Eve Hamelin,Andrés Pizzorno,Guy Boivin,Manuel Rosa-Calatrava,Julia Dubois

DOI: https://doi.org/10.1038/s41541-024-00899-9

2024-06-21

npj Vaccines

Abstract:Live-Attenuated Vaccines (LAVs) stimulate robust mucosal and cellular responses and have the potential to protect against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV), the main etiologic agents of viral bronchiolitis and pneumonia in children. We inserted the RSV-F gene into an HMPV-based LAV (Metavac®) we previously validated for the protection of mice against HMPV challenge, and rescued a replicative recombinant virus (Metavac®-RSV), exposing both RSV- and HMPV-F proteins at the virion surface and expressing them in reconstructed human airway epithelium models. When administered to BALB/c mice by the intranasal route, bivalent Metavac®-RSV demonstrated its capacity to replicate with reduced lung inflammatory score and to protect against both RSV and lethal HMPV challenges in vaccinated mice while inducing strong IgG and broad RSV and HMPV neutralizing antibody responses. Altogether, our results showed the versatility of the Metavac® platform and suggested that Metavac®-RSV is a promising mucosal bivalent LAV candidate to prevent pneumovirus-induced diseases.

immunology,medicine, research & experimental

Mitochondrial transport of K+ and Mg2+.

Chimeric Measles Virus (MV/RSV), Having Ectodomains of Respiratory Syncytial Virus (RSV) F and G Proteins Instead of Measles Envelope Proteins, Induced Protective Antibodies against RSV

Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses

Pathogenicity and Immunogenicity of Recombinant Methyltransferase-Defective Vesicular Stomatitis Virus

Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines

Cloning of Hemagglutinin Gene of Edmonston Vaccine Strain of Measles Virus and Fusion Protein Expression in Escherichia Coli

A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection

A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models

Involvement of capsular polysaccharide via a TLR2/NF-kappaB pathway in Vibrio vulnificus-induced IL-8 secretion of human intestinal epithelial cells.

MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination

Protective efficacy of a novel recombinant influenza virus carrying partial human metapneumovirus F protein epitopes

[Acutrak headless compression screw fixation for the treatment of scaphoid non-union].

Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats

Diagnostic performance of venous lactate on arrival at the emergency department for myocardial infarction.

Measles Virus-Based Vaccine Expressing Membrane-Anchored Spike of SARS-CoV-2 Inducing Efficacious Systemic and Mucosal Humoral Immunity in Hamsters

Recombinant rabies virus expressing chimeric Omp31/sodC or AHCY gene from Brucella melitensis elicits high level of antibodies and secretary cytokines in mice

Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice

Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease

Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice